Icosagen

A private, independent family business, Icosagen has advanced therapeutic proteins from mammalian cells for 26 years, uniquely combining pre-clinical CRO and clinical CDMO capabilities at one site to advance molecules from discovery through R&D into stable IcoCell CHO cell lines and GMP manufacturing. Covering monoclonal antibodies, complex multi-specifics, ADCs and recombinant proteins, the company accelerates programs for more than 100 biotechs annually by eliminating error-prone tech transfers.